BridgeBio Pharma, Inc. — Director's Dealing 2026

Mar 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2026-02-27

Reporting Person: Valantine Hannah (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-27	Common Stock	M	25484	$48.45	Acquired	32949	Direct
2026-02-27	Common Stock	S	14584	$67.0793	Disposed	18365	Direct
2026-02-27	Common Stock	S	10900	$67.8437	Disposed	7465	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-27	Stock Option (Right to Buy)	$48.45	M	25484	Disposed	2031-10-24	Common Stock (25484)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	398	Indirect

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.

F2: Represents the weighted average sale price of the shares sold from $66.42 to $67.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3: Represents the weighted average sale price of the shares sold from $67.42 to $68.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F4: The stock option vests and becomes exercisable in three annual installments after October 25, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.